Completed PHASE1 INTERVENTIONAL 1-arm NCT00003191

Fenretinide in Treating Children With Solid Tumors

A Phase I Study of Fenretinide (NSC #374551) in Children With High Risk Solid Tumors

Sponsor: National Cancer Institute (NCI)

Conditions Neuroblastoma Unspecified Childhood Solid Tumor, Protocol Specific

Interventions fenretinide

Updated 7 times since 2017 Last updated: Feb 6, 2013 Started: Mar 31, 1998 Primary completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00003191, this PHASE1 trial focuses on Neuroblastoma and Unspecified Childhood Solid Tumor, Protocol Specific and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 1998, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Cincinnati, United States , Columbus, United States , Duarte, United States , Houston, United States , Indianapolis, United States , Kansas City, United States , Long Beach, United States , Los Angeles, United States , Madison, United States and 13 more locations